T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
about
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.The immune contexture in cancer prognosis and treatment.Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.Immune checkpoint blockade in infectious diseases.Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice.Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Cordycepin and a preparation from Cordyceps militaris inhibit malignant transformation and proliferation by decreasing EGFR and IL-17RA signaling in a murine oral cancer model.Case series of pleomorphic carcinomas of the lung treated with nivolumab.Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy.Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade.Liver sampling: a vital window into HBV pathogenesis on the path to functional cure.Immune checkpoint inhibitors in advanced non-small cell lung cancer.Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.Liquid biomarkers in melanoma: detection and discovery.The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Detection and localization of surgically resectable cancers with a multi-analyte blood test.Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.Inhibitors of the PD-1 Pathway in Tumor Therapy.Mechanisms of resistance to immune checkpoint inhibitors.Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.Notable advances 2017.LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.Improving immune-vascular crosstalk for cancer immunotherapy.14-3-3ζ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes.Emerging biomarkers for cancer immunotherapy in melanoma.A roadmap towards personalized immunology.CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation.PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.
P2860
Q38629357-EB63D6EF-28B1-4DA6-8C63-61B90EF1BEBCQ39456999-D075F9DF-BA84-46D9-A1F4-6BBBC5D8AFB0Q40056869-5D4E6C2D-D591-4DB6-B398-B7BA0D9B6B67Q40091164-B0A440E9-148E-4DD0-A542-FA38E885DF13Q40115962-A31104EE-3921-4211-B6FE-B0281B68091FQ41921732-5545F91E-994F-4266-B262-934E52F16B31Q41990100-0FE5C4EF-0624-4C2F-B6F3-70A6F220425AQ42378297-A8BDB581-336D-46EB-9B0F-60AFA117CC8FQ45066081-FA1A5EE3-9DC4-42D1-8895-D25717ADA17FQ47120629-F9742676-E2D3-48E8-A3D9-D13313CC5A8FQ47139326-997A3050-E034-4F1D-B0B1-3FDD7AA52220Q47148618-2B7E80F5-5B03-4875-A014-6340E80A207EQ47151168-EA2BA1F0-E15B-42C2-85D1-64223BACEC26Q47225234-B39CACBA-54A4-43EF-9C0A-2FD8FF81D4A1Q47227422-A427BE94-E5BA-4238-94CB-641207EDA954Q47292249-B230F762-42D0-48D3-8FD5-9EECBC4C57BEQ47382765-E6A6C559-FDD8-444B-852F-E8C3E14F31A3Q47552989-AB777054-95B1-4D88-B3B0-E94C737ED242Q47553894-6CE00986-38B9-4B88-BB71-81D2249844F2Q47563451-E4A412D8-4E75-48C8-8C1D-0636FE060690Q47614555-C5BCCDBE-8B21-4C50-856A-BA3B9A497CC6Q47625086-8B97219D-5746-438F-AE42-9692C109D452Q47726847-B0259418-92D8-491C-BC77-569CCFAE459CQ47794460-2431D9D4-5666-4FEA-89CA-E8D09DFECDF6Q47958949-4B0567AB-F918-4133-8F25-219CF3FD5C80Q48185876-911D7D14-2784-49F5-AC02-DB6DBFB4E83DQ48216212-F83AB317-E3AD-41CF-8B8B-3AB67A26C82BQ48226736-3ACFA979-6DA7-46D1-A89B-51E6C4ED765BQ48293633-2E204114-1CA1-431D-BE8F-F260E8F09B83Q49537326-6FC3A140-8455-4F29-9F21-79E68F633066Q49698755-1ABEC602-7EC3-4CFC-9068-A4FE61D44A16Q50030341-B6C62B7B-E0F3-44D4-83FF-CAE5F781E124Q50034376-4ACE1FD4-3CA2-485F-BF15-08BA83A0D6ACQ50044559-094CBDE5-D77F-416A-8461-F84833301FDAQ50051034-6732C0CA-ED38-4C67-972A-32C960C51B26Q50054912-08058579-C679-4C19-A4D0-F43B5ECD32E8Q50058145-B498A789-E04C-4227-944F-095A45E06F65Q50104991-D3955EAF-DE35-4238-B874-08F65498DBB2Q50125551-6E120A84-F139-4A09-81DF-0A33A17529A4Q52668712-4123FC1E-6D78-4717-8FEF-0555D7E5EBAA
P2860
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
@en
type
label
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
@en
prefLabel
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
@en
P2093
P2860
P50
P356
P1433
P1476
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
@en
P2093
Alexander C Huang
Bertram Bengsch
Bradley Wubbenhorst
Brandon Wenz
Deborah Kuk
E John Wherry
Felix Quagliarello
Giorgos C Karakousis
Jedd D Wolchok
Josephine R Giles
P2860
P2888
P356
10.1038/NATURE22079
P407
P577
2017-04-10T00:00:00Z